Discontinuation of ASP0892 DNA Vaccine Development and Impairment Loss
A specific drug development program involving the discontinuation of development of the ASP0892 DNA vaccine and the resulting recognition of a significant impairment loss on development-related intangible assets and other assets.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.